2023 Q3 Form 10-Q Financial Statement

#000141057823001833 Filed on August 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.100M $1.986M
YoY Change -13.77% -32.39%
% of Gross Profit
Research & Development $7.313M $6.308M
YoY Change 35.92% 40.23%
% of Gross Profit
Depreciation & Amortization $40.00K $38.65K
YoY Change 21.36% 14.01%
% of Gross Profit
Operating Expenses $7.313M $6.308M
YoY Change 35.92% 40.23%
Operating Profit -$9.413M -$8.294M
YoY Change 20.45% 11.55%
Interest Expense $51.11K $72.78K
YoY Change 1127.43% 15030.98%
% of Operating Profit
Other Income/Expense, Net -$4.319M $72.78K
YoY Change -103819.74% 15030.98%
Pretax Income -$13.73M -$8.221M
YoY Change 75.77% 10.57%
Income Tax
% Of Pretax Income
Net Earnings -$13.73M -$8.221M
YoY Change 75.8% 10.57%
Net Earnings / Revenue
Basic Earnings Per Share -$1.21 -$0.73
Diluted Earnings Per Share -$1.21 -$0.73
COMMON SHARES
Basic Shares Outstanding 9.741M 9.741M
Diluted Shares Outstanding 11.31M 11.26M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $18.99M $5.153M
YoY Change 6.77% -79.23%
Cash & Equivalents $18.99M $5.153M
Short-Term Investments
Other Short-Term Assets $1.120M $456.7K
YoY Change 14.76% -4.79%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $20.11M $5.610M
YoY Change 7.19% -77.81%
LONG-TERM ASSETS
Property, Plant & Equipment $893.5K $337.4K
YoY Change 163.62% -7.51%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $6.214K $6.214K
YoY Change -92.35% -92.35%
Total Long-Term Assets $1.441M $899.5K
YoY Change 158.1% 48.15%
TOTAL ASSETS
Total Short-Term Assets $20.11M $5.610M
Total Long-Term Assets $1.441M $899.5K
Total Assets $21.55M $6.509M
YoY Change 11.55% -74.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.810M $6.392M
YoY Change 22.66% 17.01%
Accrued Expenses $60.00K $53.64K
YoY Change -59.51% -62.71%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $16.47M $6.445M
YoY Change 152.81% 14.97%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $510.0K $530.9K
YoY Change 848.48% 475.71%
Total Long-Term Liabilities $510.0K $530.9K
YoY Change 848.48% 475.71%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.47M $6.445M
Total Long-Term Liabilities $510.0K $530.9K
Total Liabilities $16.98M $6.976M
YoY Change 158.54% 22.42%
SHAREHOLDERS EQUITY
Retained Earnings -$210.0M -$196.3M
YoY Change 21.91% 19.35%
Common Stock $99.00 $97.00
YoY Change 62.3% 59.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$13.35M -$467.0K
YoY Change
Total Liabilities & Shareholders Equity $21.55M $6.509M
YoY Change 11.55% -74.86%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$13.73M -$8.221M
YoY Change 75.8% 10.57%
Depreciation, Depletion And Amortization $40.00K $38.65K
YoY Change 21.36% 14.01%
Cash From Operating Activities -$8.070M -$7.530M
YoY Change 15.07% 30.78%
INVESTING ACTIVITIES
Capital Expenditures $600.0K $0.00
YoY Change -8586.56% -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$600.0K $0.00
YoY Change 8386.56% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 22.50M 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -8.070M -7.530M
Cash From Investing Activities -600.0K 0.000
Cash From Financing Activities 22.50M 0.000
Net Change In Cash 13.83M -7.530M
YoY Change -297.0% 29.19%
FREE CASH FLOW
Cash From Operating Activities -$8.070M -$7.530M
Capital Expenditures $600.0K $0.00
Free Cash Flow -$8.670M -$7.530M
YoY Change 23.75% 32.41%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6308430
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4498657
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Central Index Key
EntityCentralIndexKey
0001279704
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Entity Registrant Name
EntityRegistrantName
Cellectar Biosciences, Inc.
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
111
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
111
CY2022Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.10
CY2022Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.10
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9740507
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9385272
CY2023Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P60M
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
1-36598
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
04-3321804
dei Entity Address Address Line1
EntityAddressAddressLine1
100 Campus Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
Florham Park
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07932
dei City Area Code
CityAreaCode
608
dei Local Phone Number
LocalPhoneNumber
441-8120
dei Security12b Title
Security12bTitle
Common stock, par value $0.00001
dei Trading Symbol
TradingSymbol
CLRB
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
9740507
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5152972
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19866358
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
456679
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
663243
CY2023Q2 us-gaap Assets Current
AssetsCurrent
5609651
CY2022Q4 us-gaap Assets Current
AssetsCurrent
20529601
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
337434
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
418641
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
532300
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
560334
CY2023Q2 us-gaap Long Term Investments
LongTermInvestments
23566
CY2022Q4 us-gaap Long Term Investments
LongTermInvestments
75000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6214
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6214
CY2023Q2 us-gaap Assets
Assets
6509165
CY2022Q4 us-gaap Assets
Assets
21589790
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
6391673
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
5478443
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
53640
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
50847
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
6445313
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5529290
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
530856
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
552981
CY2023Q2 us-gaap Liabilities
Liabilities
6976169
CY2022Q4 us-gaap Liabilities
Liabilities
6082271
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7000
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
111
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
111
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
1382023
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
1382023
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9740507
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9385272
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
97
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
94
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
194452408
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
193624445
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-196301532
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-179499043
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-467004
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
15507519
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6509165
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21589790
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12962524
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8385656
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1985572
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2936867
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4036779
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5190095
CY2023Q2 us-gaap Costs And Expenses
CostsAndExpenses
8294002
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
7435524
us-gaap Costs And Expenses
CostsAndExpenses
16999303
us-gaap Costs And Expenses
CostsAndExpenses
13575751
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8294002
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7435524
us-gaap Operating Income Loss
OperatingIncomeLoss
-16999303
us-gaap Operating Income Loss
OperatingIncomeLoss
-13575751
CY2023Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
72780
CY2022Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
481
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
196814
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
911
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
72780
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
481
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
196814
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
911
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-8221222
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-7435043
us-gaap Net Income Loss
NetIncomeLoss
-16802489
us-gaap Net Income Loss
NetIncomeLoss
-13574840
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.73
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.73
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.22
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.49
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.49
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.22
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.22
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11261217
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11261217
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6110124
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6110124
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11261217
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11261217
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6110125
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6110125
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
33045154
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
303805
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-6139797
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
27209162
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
419953
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-7435043
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
20194072
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
15507519
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
408206
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
3
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-8581267
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
7334461
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
419757
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-8221222
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-467004
us-gaap Net Income Loss
NetIncomeLoss
-16802489
us-gaap Net Income Loss
NetIncomeLoss
-13574840
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
81207
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
77316
us-gaap Share Based Compensation
ShareBasedCompensation
827963
us-gaap Share Based Compensation
ShareBasedCompensation
723758
clrb Non Cash Lease Expense
NonCashLeaseExpense
28034
clrb Non Cash Lease Expense
NonCashLeaseExpense
43533
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-3386
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-257998
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-387817
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-19332
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-65684
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
913230
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1607353
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14713389
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10797361
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
101049
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-101049
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
3
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-14713386
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10898410
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19866358
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35703975
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5152972
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24805565
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-196302000
us-gaap Net Income Loss
NetIncomeLoss
-16802000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
71000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
132000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
147000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
150000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
153000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
207000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
860000
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
275000
us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Concentration of Credit Risk</span> — Financial instruments that subject the Company to credit risk consist of cash and cash equivalents on deposit with financial institutions. The Company’s excess cash as of June 30, 2023 and December 31, 2022 is on deposit in interest-bearing accounts with well-established financial institutions. At times, such amounts may exceed the FDIC insurance limits. As of June 30, 2023, and December 31, 2022, uninsured cash balances totaled approximately $4,653,000 and $19,400,000, respectively.</p>
CY2023Q2 us-gaap Cash Uninsured Amount
CashUninsuredAmount
4653000
CY2022Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
19400000
clrb Proceeds From Research And Development
ProceedsFromResearchAndDevelopment
647000
CY2023Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
8235189
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1479000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
340250
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
585000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9043346
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2331809
CY2023Q2 us-gaap Area Of Land
AreaOfLand
3983
CY2023Q2 us-gaap Lease Deposit Liability
LeaseDepositLiability
23566
us-gaap Payments For Rent
PaymentsForRent
11800
clrb Increase In Percentage Of Rent
IncreaseInPercentageOfRent
0.02
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.14
CY2018Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.10

Files In Submission

Name View Source Status
clrb-20230630_pre.xml Edgar Link unprocessable
clrb-20230630_lab.xml Edgar Link unprocessable
0001410578-23-001833-index-headers.html Edgar Link pending
0001410578-23-001833-index.html Edgar Link pending
0001410578-23-001833.txt Edgar Link pending
0001410578-23-001833-xbrl.zip Edgar Link pending
clrb-20230630.xsd Edgar Link pending
clrb-20230630x10q.htm Edgar Link pending
clrb-20230630xex31d1.htm Edgar Link pending
clrb-20230630xex31d2.htm Edgar Link pending
clrb-20230630x10q_htm.xml Edgar Link completed
clrb-20230630xex32d1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
clrb-20230630_cal.xml Edgar Link unprocessable
clrb-20230630_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable